Protocols Calculator Guides Glossary About Calculator →
Research use only.  Educational reference. Not medical advice. Not for human consumption.
// catalog · v3

Peptide protocols, indexed.

Research-grade dosage protocols sourced from peer-reviewed literature. Each full protocol contains dosing tables, reconstitution math, mechanism notes, and primary citations.

100+full protocols built
100+peptides cataloged
8research categories
0vendor placements
// 01

Recovery & Tissue Repair

22 protocols
● built
BPC-157 / 5 mg vial
5 mg vial · 3 mL BAC → 1.67 mg/mL · 1 unit = 16.67 mcg
5 mgRUO
→ open protocol
 ● built
BPC-157 / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33.33 mcg
10 mgRUO
→ open protocol
 ● built
BPC-157 / 20 mg vial
20 mg vial · 3 mL BAC → 6.67 mg/mL · 1 unit = 66.67 mcg
20 mgRUO
→ open protocol
 ● built
TB-500 (Thymosin Beta-4 Fragment) / 5 mg vial
5 mg vial · 3 mL BAC → 1.67 mg/mL · 1 unit = 16.67 mcg
5 mgRUO
→ open protocol
 ● built
TB-500 (Thymosin Beta-4 Fragment) / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33.33 mcg
10 mgRUO
→ open protocol
 ● built
TB-500 (Thymosin Beta-4 Fragment) / 20 mg vial
20 mg vial · 3 mL BAC → 6.67 mg/mL · 1 unit = 66.67 mcg
20 mgRUO
→ open protocol
 ● built
KPV / 10 mg vial
Tripeptide fragment of α-MSH. Studied for anti-inflammatory properties, gut mucosa research, and NF-κB inhibition.
10 mgRUO
→ open protocol
 ● built
LL-37 (Cathelicidin) / 5 mg vial
Cathelicidin-derived antimicrobial peptide studied for immune modulation, wound healing, and antimicrobial defense.
5 mgRUO
→ open protocol
 ● built
Thymosin Alpha-1 / 10 mg vial
Immune-modulating peptide from thymosin fraction 5. Studied for immune dysregulation and immune senescence.
10 mgRUO
→ open protocol
 ● built
VIP (Vasoactive Intestinal Peptide) / 10 mg vial
Vasoactive Intestinal Peptide. Studied for chronic inflammatory response syndrome (CIRS), immune balance, and anti-inflammatory pathways.
10 mgRUO
→ open protocol
 ● built
ARA-290 (Cibinetide) / 3 vial sizes
Erythropoietin-derived peptide. Studied for diabetic neuropathy, sarcoidosis-related small-fiber neuropathy, and tissue protection.
All sizesRUO
→ open protocol
● built
ARA-290 (Cibinetide) / 10 mg vial
10 mg vial of ARA-290 (Cibinetide). EPOR agonist studied for neuropathic pain and tissue repair.
10 mgRUO
→ open protocol
 ● built
ARA-290 (Cibinetide) / 16 mg vial
16 mg vial · 2 mL BAC → 8 mg/mL · 1 unit = 80 mcg
16 mgRUO
→ open protocol
 ● built
ARA-290 (Cibinetide) / 40 mg vial
40 mg vial · 2 mL BAC → 20 mg/mL · 1 unit = 200 mcg
40 mgRUO
→ open protocol
 ● built
Glutathione / 3 vial sizes
Tripeptide master antioxidant. Studied for oxidative-stress reduction, hepatic detoxification support, and immune function.
All sizesRUO
→ open protocol
● built
Glutathione / 1200 mg vial
1,200 mg vial. Master antioxidant — IV or sub-Q for oxidative stress, detoxification, and skin brightening protocols.
1200 mgRUO
→ open protocol
● built
Glutathione / 1500 mg vial
1,500 mg vial. Highest available concentration for advanced antioxidant and detox protocols.
1500 mgRUO
→ open protocol
 ● built
Glutathione / 600 mg vial
600 mg vial · 2 mL BAC → 300 mg/mL · 1 unit = 3000 mcg
600 mgRUO
→ open protocol
 ● built
PNC-27 / 2 vial sizes
p53-derived membrane-disrupting peptide. Studied as an investigational anti-cancer compound that selectively targets HDM-2 expressing cells.
All sizesRUO
→ open protocol
 ● built
PNC-27 / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33.33 mcg
10 mgRUO
→ open protocol
 ● built
PNC-27 / 30 mg vial
30 mg vial · 3 mL BAC → 10 mg/mL · 1 unit = 100 mcg
30 mgRUO
→ open protocol
 ● built
MGF / 5 mg vial
Mechano Growth Factor (IGF-1Ec splice variant). Distinct from PEG-MGF — short half-life; localized tissue repair signal. Studied for muscle satellite cell activation.
5 mgRUO
→ open protocol
// 02

GH Secretagogues & Growth Hormone

19 protocols
● built
CJC-1295 + Ipamorelin Blend / 10 mg vial
GHRH analog + selective GHS. Complementary pathways for synergistic pulsatile GH release.
10 mgRUO
→ open protocol
● built
CJC-1295 no-DAC + Ipamorelin Blend / 5 mg + 5 mg vial
5 mg CJC-1295 no-DAC + 5 mg Ipamorelin blend. Same synergistic GHRH+GHRP combination at lower total vial concentration.
5 mg + 5 mgRUO
→ open protocol
 ● built
Ipamorelin / 10 mg vial
First selective GH secretagogue. GH release without cortisol/ACTH elevation. Low desensitization profile.
10 mgRUO
→ open protocol
 ● built
GHRP-2 / 5 mg vial
Potent GHRP. Strong GH stimulation via dual pituitary + hypothalamic sites. Mild cortisol/ACTH elevation at higher doses.
5 mgRUO
→ open protocol
 ● built
GHRP-6 / 10 mg vial
Classic GHRP with the strongest appetite stimulation of any secretagogue. Cortisol elevation at high doses.
10 mgRUO
→ open protocol
 ● built
Hexarelin / 5 mg vial
Most potent GHRP studied. Strong GH release plus cardioprotective effects. Significant desensitization at chronic high doses.
5 mgRUO
→ open protocol
 ● built
Sermorelin / 10 mg vial
GHRH(1–29) analog. Preserves IGF-1 negative feedback. First GHRH analog studied (pediatric GHD). Before-sleep dosing.
10 mgRUO
→ open protocol
 ● built
CJC-1295 with DAC / 5 mg vial
Long-acting GHRH analog with Drug Affinity Complex. ~6–8 day half-life via albumin binding. Once-weekly dosing.
5 mgRUO
→ open protocol
 ● built
CJC-1295 without DAC / 2 vial sizes
Short-acting GHRH analog (~30 min half-life). Produces natural GH pulses. Typically combined with GHRPs.
All sizesRUO
→ open protocol
● built
CJC-1295 without DAC / 5 mg vial
5 mg vial of CJC-1295 without DAC (Mod GRF 1-29). Short-acting GHRH analog for daily GH pulse protocols.
5 mgRUO
→ open protocol
 ● built
CJC-1295 without DAC (Mod GRF 1-29) / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33.33 mcg
10 mgRUO
→ open protocol
 ● built
HGH 191AA (Somatropin) / 24 IU vial
24 IU vial · 3 mL BAC → 8 IU/mL · 1 unit = 0.08 IU
24 IURUO
→ open protocol
 ● built
HGH 191AA (Somatropin) / 36 IU vial
36 IU vial · 3 mL BAC → 12 IU/mL · 1 unit = 0.12 IU
36 IURUO
→ open protocol
 ● built
HGH 191AA / 50 IU vial
50 IU vial · 3 mL BAC → 16.67 IU/mL · 1 unit = 0.1667 IU
50 IURUO
→ open protocol
 ● built
Tesamorelin / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33.33 mcg
10 mgRUO
→ open protocol
 ● built
Tesamorelin / 20 mg vial
20 mg vial · 3 mL BAC → 6.67 mg/mL · 1 unit = 66.67 mcg
20 mgRUO
→ open protocol
 ● built
IGF-1 LR3 / 1 mg vial
Long-acting IGF-1 analog. Downstream GH mediator with extended receptor binding. Direct anabolic and recovery effects.
1 mgRUO
→ open protocol
 ● built
PEG-MGF / 2 mg vial
PEGylated mechano growth factor. IGF-1 splice variant studied for muscle satellite cell activation and post-injury recovery.
2 mgRUO
→ open protocol
 ● built
FST 344 (Follistatin) / 1 mg vial
Myostatin inhibitor. Studied for muscle hypertrophy via GDF-8 / activin pathway antagonism. Two main isoforms compared.
1 mgRUO
→ open protocol
// 03

Metabolic & Weight Management

43 protocols
● built
Retatrutide GLP-3 RT / 5 mg vial
5 mg vial · 1 mL BAC → 5 mg/mL · 1 unit = 50 mcg
5 mgRUO
→ open protocol
 ● built
Retatrutide GLP-3 RT / 10 mg vial
10 mg vial · 1 mL BAC → 10 mg/mL · 1 unit = 100 mcg
10 mgRUO
→ open protocol
 ● built
Retatrutide GLP-3 RT / 20 mg vial
20 mg vial · 2 mL BAC → 10 mg/mL · 1 unit = 100 mcg
20 mgRUO
→ open protocol
 ● built
Retatrutide GLP-3 RT / 30 mg vial
30 mg vial · 3 mL BAC → 10 mg/mL · 1 unit = 100 mcg
30 mgRUO
→ open protocol
 ● built
Retatrutide GLP-3 RT / 40 mg vial
40 mg vial · 2 mL BAC → 20 mg/mL · 1 unit = 200 mcg
40 mgRUO
→ open protocol
 ● built
Retatrutide GLP-3 RT / 60 mg vial
60 mg vial · 3 mL BAC → 20 mg/mL · 1 unit = 200 mcg
60 mgRUO
→ open protocol
 ● built
Semaglutide GLP-1 SM / 5 mg vial
5 mg vial · 2 mL BAC → 2.5 mg/mL · 1 unit = 25 mcg
5 mgRUO
→ open protocol
 ● built
Semaglutide GLP-1 SM / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33.33 mcg
10 mgRUO
→ open protocol
 ● built
Semaglutide GLP-1 SM / 20 mg vial
20 mg vial · 3 mL BAC → 6.67 mg/mL · 1 unit = 66.67 mcg
20 mgRUO
→ open protocol
● built
GLP-1 SM / Semaglutide / 10 mg vial
10 mg semaglutide vial. GLP-1 receptor agonist for metabolic and weight research.
10 mgRUO
→ open protocol
● built
GLP-1 SM / Semaglutide / 30 mg vial
30 mg semaglutide vial. Extended supply for longer GLP-1 research protocols.
30 mgRUO
→ open protocol
● built
GLP-2 TZ / Tirzepatide / 10 mg vial
10 mg tirzepatide (GLP-1/GIP dual agonist) for metabolic research.
10 mgRUO
→ open protocol
● built
GLP-2 TZ / Tirzepatide / 20 mg vial
20 mg tirzepatide vial.
20 mgRUO
→ open protocol
● built
GLP-2 TZ / Tirzepatide / 30 mg vial
30 mg tirzepatide vial.
30 mgRUO
→ open protocol
● built
GLP-2 TZ / Tirzepatide / 40 mg vial
40 mg tirzepatide vial — highest GLP2-TZ concentration available.
40 mgRUO
→ open protocol
● built
GLP-3 RT / Retatrutide / 10 mg vial
10 mg retatrutide (triple GLP-1/GIP/glucagon agonist). Most potent GLP class.
10 mgRUO
→ open protocol
● built
GLP-3 RT / Retatrutide / 20 mg vial
20 mg retatrutide vial.
20 mgRUO
→ open protocol
● built
GLP-3 RT / Retatrutide / 30 mg vial
30 mg retatrutide vial.
30 mgRUO
→ open protocol
● built
GLP-3 RT / Retatrutide / 40 mg vial
40 mg retatrutide vial.
40 mgRUO
→ open protocol
● built
GLP-3 RT / Retatrutide / 60 mg vial
60 mg retatrutide — highest available concentration for advanced research.
60 mgRUO
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 5 mg vial
5 mg vial · 2 mL BAC → 2.5 mg/mL · 1 unit = 25 mcg
5 mgRUO
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 10 mg vial
10 mg vial · 2 mL BAC → 5 mg/mL · 1 unit = 50 mcg
10 mgRUO
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 15 mg vial
15 mg vial · 2 mL BAC → 7.5 mg/mL · 1 unit = 75 mcg
15 mgRUO
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 20 mg vial
20 mg vial · 2 mL BAC → 10 mg/mL · 1 unit = 100 mcg
20 mgRUO
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 30 mg vial
30 mg vial · 3 mL BAC → 10 mg/mL · 1 unit = 100 mcg
30 mgRUO
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 40 mg vial
40 mg vial · 2 mL BAC → 20 mg/mL · 1 unit = 200 mcg
40 mgRUO
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 50 mg vial
50 mg vial · 2.5 mL BAC → 20 mg/mL · 1 unit = 200 mcg
50 mgRUO
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 60 mg vial
60 mg vial · 3 mL BAC → 20 mg/mL · 1 unit = 200 mcg
60 mgRUO
→ open protocol
 ● built
Mazdutide / 100 mg vial
Dual GLP-1 / glucagon receptor agonist. Phase 3 weight-management investigational compound. Differentiated from triple-agonist class.
100 mgRUO
→ open protocol
 ● built
Cagrilintide / 10 mg vial
Long-acting amylin analog. Under investigation in combination with semaglutide (CagriSema). Satiety modulation.
10 mgRUO
→ open protocol
 ● built
AOD-9604 / 5 mg vial
5 mg vial · 3 mL BAC → 1.67 mg/mL · 1 unit = 16.67 mcg
5 mgRUO
→ open protocol
 ● built
AOD-9604 / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33.33 mcg
10 mgRUO
→ open protocol
 ● built
AOD-9604 / 20 mg vial
20 mg vial · 3 mL BAC → 6.67 mg/mL · 1 unit = 66.67 mcg
20 mgRUO
→ open protocol
 ● built
5-Amino-1MQ / 50 mg vial
NNMT inhibitor studied for adipocyte reduction in metabolic syndrome models. Oral research compound.
50 mgRUO
→ open protocol
 ● built
AICAR / 50 mg vial
AMPK activator. Studied as an exercise mimetic — increasing fatty-acid oxidation and endurance capacity in preclinical models.
50 mgRUO
→ open protocol
 ● built
SLU-PP-332 / 10 mg vial
ERR (estrogen-related receptor) agonist. Novel exercise-mimetic compound studied for muscle endurance and fat oxidation.
10 mgRUO
→ open protocol
 ● built
MIC Lipo-c + B12 / 30 mg vial
Lipotropic blend of methionine, inositol, choline, plus B12. Studied for hepatic fat metabolism support and energy.
30 mgRUO
→ open protocol
 ● built
Survodutide / 10 mg vial
GLP-1/glucagon dual agonist. Phase 2: 12.5–14.9% weight loss over 46 weeks. Weekly titration 0.6→6 mg.
10 mgRUO
→ open protocol
 ● built
Adipotide / 10 mg vial
⚠ Prohibitin-targeting peptidomimetic. Destroys adipose vasculature. Clinical development discontinued due to renal toxicity.
10 mgRUO
→ open protocol
 ● built
L-Carnitine / 200 mg vial
Mitochondrial fatty-acid transporter. Sub-Q bypasses TMAO production of oral route. 100% bioavailability.
200 mgRUO
→ open protocol
● built
Lipo-B (MIC + B12)
Compounded lipotropic blend of methionine, inositol, choline, and B12. Hepatic fat metabolism support. Pre-mixed.
RUO
→ open protocol
● built
Lipo-C (MIC + L-Carnitine)
Lipotropic blend with L-Carnitine for mitochondrial fatty-acid transport. Supports hepatic fat export and β-oxidation. Pre-mixed.
RUO
→ open protocol
● built
Vitamin B12 (Cyanocobalamin) Injectable
Injectable cobalamin. Near-100% bioavailability regardless of intrinsic factor status. Supports methylation and neurological function.
RUO
→ open protocol
// 04

Longevity & Bioregulators

22 protocols
● built
Epitalon / 10 mg vial
10 mg vial · 2 mL BAC → 5 mg/mL · 1 unit = 50 mcg
10 mgRUO
→ open protocol
 ● built
Epitalon / 50 mg vial
50 mg vial · 2 mL BAC → 25 mg/mL · 1 unit = 250 mcg
50 mgRUO
→ open protocol
 ● built
FOXO4-DRI / 10 mg vial
FOXO4-p53 disruptor. Studied as a senolytic agent — selectively inducing apoptosis in senescent cells.
10 mgRUO
→ open protocol
 ● built
SS-31 (Elamipretide) / 10 mg vial
10 mg vial · 1 mL BAC → 10 mg/mL · 1 unit = 100 mcg
10 mgRUO
→ open protocol
 ● built
SS-31 (Elamipretide) / 50 mg vial
50 mg vial · 3 mL BAC → 16.67 mg/mL · 1 unit = 166.67 mcg
50 mgRUO
→ open protocol
 ● built
MOTS-c / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33.33 mcg
10 mgRUO
→ open protocol
 ● built
MOTS-c / 40 mg vial
40 mg vial · 3 mL BAC → 13.33 mg/mL · 1 unit = 133.33 mcg
40 mgRUO
→ open protocol
 ● built
MOTS-c (40 mg Vial / 4 mL Option) / 40 mg MOTS-C vial
40 mg MOTS-C vial · 4 mL BAC → 10 mg/mL · 1 unit = 100 mcg
40 mg MOTS-CRUO
→ open protocol
 ● built
NAD+ / 500 mg vial
500 mg vial · 3.0 mL BAC → 166.67 mg/mL · 1 unit = ?
500 mgRUO
→ open protocol
 ● built
NAD+ / 1,000 mg vial
1,000 mg vial · 3.0 mL BAC → 333.33 mg/mL · 1 unit = ?
1,000 mgRUO
→ open protocol
 ● built
Humanin / 10 mg vial
Mitochondrial-derived neuroprotective peptide. Studied for Alzheimer's models, metabolic regulation, and aging biomarkers.
10 mgRUO
→ open protocol
 ● built
Pinealon / 20 mg vial
Tripeptide bioregulator from pineal gland. Studied for circadian regulation, sleep architecture, and neuroretinal aging.
20 mgRUO
→ open protocol
 ● built
Cartalax / 20 mg vial
Tripeptide bioregulator from cartilage. Studied for musculoskeletal aging and connective tissue gene expression.
20 mgRUO
→ open protocol
 ● built
Chonluten / 10 mg vial
Tripeptide bioregulator from bronchial mucosa. Studied for respiratory epithelial aging and pulmonary biomarkers.
10 mgRUO
→ open protocol
 ● built
Bronchogen / 10 mg vial
Tetrapeptide bioregulator. Studied for bronchial epithelium repair, pulmonary function, and respiratory aging biomarkers.
10 mgRUO
→ open protocol
 ● built
Prostamax / 20 mg vial
Tripeptide bioregulator. Studied for prostate-tissue gene expression and male reproductive-tissue aging biomarkers.
20 mgRUO
→ open protocol
 ● built
Cortagen / 20 mg vial
Cortical tetrapeptide bioregulator (Ala-Glu-Asp-Pro). Studied for cognitive support and post-stroke neural recovery.
20 mgRUO
→ open protocol
 ● built
Ovagen / 20 mg vial
Hepatic tripeptide bioregulator (Glu-Asp-Leu). Studied for liver support and detoxification pathway modulation.
20 mgRUO
→ open protocol
 ● built
Testagen / 20 mg vial
Testicular tetrapeptide bioregulator (Lys-Glu-Asp-Gly). Studied for male reproductive support and testosterone axis modulation.
20 mgRUO
→ open protocol
 ● built
Vesugen / 20 mg vial
Vascular tripeptide bioregulator (Lys-Glu-Asp). Studied for endothelial repair and cardiovascular aging.
20 mgRUO
→ open protocol
 ● built
Vilon / 20 mg vial
Immune dipeptide bioregulator (Lys-Glu). Studied for T-cell function and age-related immunosenescence.
20 mgRUO
→ open protocol
 ● built
Livagen / 20 mg vial
Lymphoid tetrapeptide bioregulator (Lys-Glu-Asp-Ala). Studied for B-cell activity and humoral immune support.
20 mgRUO
→ open protocol
// 05

Skin & Cosmetic Peptides

7 protocols
● built
GHK-Cu (Copper Peptide) / 50 mg vial
50 mg vial · 3 mL BAC → 16.67 mg/mL · 1 unit = 166.67 mcg
50 mgRUO
→ open protocol
 ● built
GHK-Cu (Copper Peptide) / 100 mg vial
100 mg vial · 3 mL BAC → 33.33 mg/mL · 1 unit = 333.33 mcg
100 mgRUO
→ open protocol
 ● built
AHK-Cu / 50 mg vial
Copper tripeptide cousin of GHK-Cu. Primarily studied for hair follicle stimulation and dermal capillary health.
50 mgRUO
→ open protocol
 ● built
Melanotan I / 10 mg vial
Selective MC1R agonist. studied for erythropoietic protoporphyria. Studied for tanning and photoprotection.
10 mgRUO
→ open protocol
 ● built
Melanotan II / 10 mg vial
Non-selective melanocortin receptor agonist. Studied for skin pigmentation, photoprotection, and sexual function.
10 mgRUO
→ open protocol
 ● built
SNAP-8 / 10 mg vial
⚠ Topical only — do not inject. Acetyl octapeptide-3 for expression-line reduction. Formulate at 0.0015–0.005% in cream/serum.
10 mgRUO
→ open protocol
● built
SNAP-8 / 100 mg vial
100 mg vial — 10 mL BAC → 10 mg/mL. High-volume cosmetic peptide vial for extended wrinkle-reduction protocols.
100 mgRUO
→ open protocol
// 06

Hormonal & Sexual Health

8 protocols
● built
HCG (Human Chorionic Gonadotropin) / 10,000 IU vial
Human chorionic gonadotropin. LH-mimetic. studied for cryptorchidism and hypogonadism. Testosterone support and fertility research.
10,000 IURUO
→ open protocol
 ● built
HMG (Human Menopausal Gonadotropin) / 75 iu vial
Human menopausal gonadotropin. FSH + LH combination studied for ovarian stimulation and fertility research applications.
75 iuRUO
→ open protocol
 ● built
PT-141 (Bremelanotide) / 10 mg vial
Melanocortin agonist (MC3R/MC4R). investigational compound studied for HSDD. CNS sexual arousal mechanism.
10 mgRUO
→ open protocol
 ● built
Gonadorelin (GnRH) / 2 mg vial
GnRH decapeptide. Stimulates pulsatile LH and FSH release from pituitary. HPG axis research.
2 mgRUO
→ open protocol
 ● built
Kisspeptin / 10 mg vial
GPR54 receptor agonist. Upstream GnRH pulse inducer. Studied for LH pulsatility and reproductive hormone research.
10 mgRUO
→ open protocol
 ● built
Oxytocin / 2 vial sizes
Nonapeptide neuromodulator. Studied for social bonding, anxiety reduction, and stress regulation. Intranasal and sub-Q routes.
All sizesRUO
→ open protocol
● built
Oxytocin / 5 mg vial
5 mg vial — 3 mL BAC water → 1.67 mg/mL. 16.7 mcg per U-100 unit. Titration 100→500 mcg/day sub-Q or intranasal.
5 mgRUO
→ open protocol
● built
Oxytocin / 10 mg vial
10 mg vial — 3 mL BAC water → 3.33 mg/mL. 33.3 mcg per U-100 unit. Titration 100→500 mcg/day sub-Q or intranasal.
10 mgRUO
→ open protocol
// 07

Cognitive & Neuroprotective

13 protocols
● built
Cerebrolysin / 60 mg vial
Porcine brain-derived neuropeptide mixture. Studied for neuroprotection, neuroplasticity, and recovery from neural injury.
60 mgRUO
→ open protocol
 ● built
Semax / 2 vial sizes
Synthetic heptapeptide ACTH analog. Studied for cognitive enhancement, neuroprotection, and BDNF upregulation.
All sizesRUO
→ open protocol
● built
Semax / 10 mg vial
10 mg vial. ACTH-derived nootropic. Intranasal or sub-Q. Studied for BDNF upregulation and cognitive enhancement.
10 mgRUO
→ open protocol
● built
Semax / 30 mg vial
30 mg vial — extended supply for longer Semax protocols or higher-dose cognitive research.
30 mgRUO
→ open protocol
 ● built
ADAMAX / 10 mg vial
Modified Semax analog with extended half-life. Studied for cognitive enhancement, BDNF upregulation, and neuroprotective signaling.
10 mgRUO
→ open protocol
 ● built
Selank / 2 vial sizes
Synthetic tuftsin analog with anxiolytic and cognitive effects. Studied for anxiety, stress, and immune function.
All sizesRUO
→ open protocol
● built
Selank / 10 mg vial
10 mg vial. Synthetic anxiolytic heptapeptide. Sub-Q or intranasal. Studied for anxiety, cognition, and immune modulation.
10 mgRUO
→ open protocol
● built
Selank / 30 mg vial
30 mg vial — extended supply for longer Selank protocols or higher-dose intranasal research.
30 mgRUO
→ open protocol
 ● built
DSIP (Delta Sleep-Inducing Peptide) / 5 mg vial
5 mg vial · 3 mL BAC → 1.67 mg/mL · 1 unit = 16.67 mcg
5 mgRUO
→ open protocol
 ● built
DSIP (Delta Sleep-Inducing Peptide) / 15 mg vial
15 mg vial · 3 mL BAC → 5 mg/mL · 1 unit = 50 mcg
15 mgRUO
→ open protocol
 ● built
Dermorphin / 5 mg vial
Heptapeptide opioid agonist (mu-receptor). Studied as an investigational analgesic with potency multiples greater than morphine.
5 mgRUO
→ open protocol
 ● built
PE 22-28 / 10 mg vial
TREK-1 channel inhibitor. Studied as a fast-acting investigational antidepressant in preclinical models.
10 mgRUO
→ open protocol
● built
Neuroxelin Blend / 48 mg total blend vial
Proprietary neuropeptide blend for cognitive support and neuroprotection. Combines cerebrolysin-derived fractions with nootropic peptides.
48 mg total blendRUO
→ open protocol
// 08

Peptide Blends

21 protocols
● built
Wolverine Blend (BPC-157 / TB-500) / 3 vial sizes
High-dose recovery blend: 10 mg BPC-157 + 10 mg TB-500. Standard and loading-phase protocols. Complementary tissue-repair mechanisms.
All sizesRUO
→ open protocol
● built
Wolverine Blend (BPC-157 / TB-500) / 5 mg vial
5 mg vial (2.5 mg BPC-157 + 2.5 mg TB-500). 2 mL BAC → 2.5 mg/mL. Titration 500–750 mcg/day sub-Q.
5 mgRUO
→ open protocol
 ● built
Wolverine Blend (BPC-157 / TB-500) / 10 mg vial
Lighter 10 mg version: 5 mg BPC-157 + 5 mg TB-500. For lower doses or shorter cycles.
10 mgRUO
→ open protocol
● built
Wolverine Blend (BPC-157 / TB-500) / 20 mg vial
20 mg vial (10 mg BPC-157 + 10 mg TB-500). 4 mL BAC → 5 mg/mL. Highest-concentration Wolverine for extended recovery cycles.
20 mgRUO
→ open protocol
 ● built
CagriSema (Cagrilintide + Semaglutide) / 5 mg vial
GLP-1 agonist + amylin analog. Phase 3 investigation. Dual satiety mechanism for weight management research.
5 mgRUO
→ open protocol
 ● built
GHRP-2 + CJC-1295 Blend / 10 mg vial
Potent GHRP + GHRH combination for amplified GH pulse. Classic synergistic secretagogue pairing.
10 mgRUO
→ open protocol
 ● built
Tesamorelin + Ipamorelin Blend / 10 mg vial
GHRH analog with strongest visceral fat evidence (HIV lipodystrophy trials) + selective GHRP. Synergistic GH release.
10 mgRUO
→ open protocol
 ● built
4X Blend (GHRP-2 / Tesamorelin / MGF / Ipamorelin) / 12 mg vial
Four-peptide stack combining tissue repair and recovery agents in a single reconstituted vial. Synergistic mechanisms for accelerated repair research.
12 mgRUO
→ open protocol
 ● built
GLOW Blend (GHK-Cu / BPC-157 / TB-500) / 70 mg vial
Skin & longevity blend pairing GHK-Cu with complementary peptides. Studied for collagen synthesis, skin remodeling, and gene-expression modulation.
70 mgRUO
→ open protocol
 ● built
KLOW Blend (GHK-Cu / KPV / BPC-157 / TB-500) / 80 mg vial
Multi-peptide combination blend for systemic recovery and tissue support. Combines complementary peptide mechanisms in a single vial.
80 mgRUO
→ open protocol
● built
RTE60 / Retatrutide / 60 mg vial
Triple+dual GLP agonist blend — Retatrutide 20mg + Tirzepatide 40mg in one vial for comprehensive metabolic research.
60 mgRUO
→ open protocol
● built
Dihexa / 5 mg vial
Nootropic peptide derived from angiotensin IV. Studied for cognitive enhancement and neuroplasticity.
5 mgRUO
→ open protocol
● built
Matrixyl / 10 mg vial
Palmitoyl Pentapeptide-4. Collagen-stimulating cosmetic peptide studied for fine line and wrinkle reduction.
10 mgRUO
→ open protocol
● built
PTD-DM / 10 mg vial
Research peptide studied for neuroprotective and cognitive applications.
10 mgRUO
→ open protocol
● built
HCG / 10,000 IU vial
10,000 IU vial of Human Chorionic Gonadotropin. Double-strength for extended hormonal protocols.
10,000 IURUO
→ open protocol
● built
Semax + Selank Blend / 10 mg vial
Dual nootropic-anxiolytic blend: Semax (BDNF upregulation) + Selank (anxiolysis). Cognitive focus with anxiety reduction.
10 mgRUO
→ open protocol
● built
Tri-Heal Blend (TB-500 / BPC-157 / KPV) / 45 mg total blend 25 mg TB-500 + 10 mg BPC-157 + 10 mg KPV vial
Triple recovery blend: TB-500 + BPC-157 + KPV. Broader repair than Wolverine blend.
45 mg total blend 25 mg TB-500 + 10 mg BPC-157 + 10 mg KPVRUO
→ open protocol
● built
Melanotan II + PT-141 Blend / 10 mg vial
Dual melanocortin blend: MT-II (tanning) + PT-141 (sexual function). Lower per-component doses.
10 mgRUO
→ open protocol
● built
CJC-1295 DAC + Ipamorelin / 5 mg + 5 mg vial
Long-acting GHRH once weekly + selective daily GHRP. Sustained background + daily GH pulses.
5 mg + 5 mgRUO
→ open protocol
● built
AOD-9604 + CJC-1295 + Ipamorelin Triple Blend / 12 mg total blend 6 mg AOD-9604 + 3 mg CJC-1295 + 3 mg Ipamorelin vial
Triple fat-loss + GH blend. AOD lipolysis + CJC GHRH + Ipamorelin GHRP. Daily fasted.
12 mg total blend 6 mg AOD-9604 + 3 mg CJC-1295 + 3 mg IpamorelinRUO
→ open protocol
● built
Relaxation PM Blend
Pre-sleep: DSIP + Selank + optional Oxytocin/Epitalon. Studied for sleep quality and pre-sleep anxiety.
RUO
→ open protocol